GenStar Therapeutics Inc. - Company Profile

BioCentury | Dec 21, 2020

Management Tracks

CFO transitions at Translate, Spero, Ziopharm, Precision, CASI, Tessa, Kiniksa and Aquestive; plus updates from 3T, Novavax, Alnylam and more

...Myers as CMO. Greenleaf is CEO of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH; TSX:AUP). Bryan joins from UroGen...

BioCentury | Dec 3, 2020

Management Tracks

Management Tracks: Zai taps Sandler as cancer head, plus moves at FibroGen, Arena, Samumed, Avita, Mersana, Frequency, Matinas, NeuBase, Allena and RA

...at Bristol Myers Squibb Co. (NYSE:BMY).Peter Pfreundschuh joined degenerative disease company Frequency Therapeutics Inc. (NASDAQ:FREQ) as CFO. He was CFO at UroGen...

BioCentury | Apr 16, 2020

Product Development

April 15 Quick Takes: TScan, Novartis team up on TCR therapies and a first for UroGen; plus Aligos, Leo, Madrigal, Merck

...FDA approves first therapy for urothelial cancer subtype FDA approved Jelmyto mitomycin gel from UroGen...
...Generic), Ontruzant (Other) Samsung Bioepis Co. Ltd. Merck & Co. Inc. Madrigal Pharmaceuticals Inc. Leo Pharma A/S Novartis AG TScan Therapeutics Inc. UroGen...

BioCentury | Mar 28, 2020

Management Tracks

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

...subsidiary of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) (see “Roivant Pockets $3B from Dainippon” ). UroGen...
...Inc. Recursion Pharmaceuticals Inc. 89bio Inc. Heptares Therapeutics Ltd. Sosei Group Corp. Fusion Pharmaceuticals Inc. Freeline Therapeutics Ltd. Seres Therapeutics Inc. Urovant Sciences Ltd. UroGen...

BioCentury | Jul 13, 2019

Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...NASDAQ:WVE) 1/24/19 $150.1 $1,268.3 $893.8 -30% Bellerophon Therapeutics Inc. (NASDAQ:BLPH) 1/23/19 $7.0 $48.1 $41.3 -14% UroGen...

BioCentury | Jun 29, 2019

Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...Pharmaceutical Inc. (NASDAQ:RARE) Triheptanoin (UX007) Treat long-chain fatty acid oxidation disorders (LC-FAOD) Submit NDA Mid-2019 UroGen...

BioCentury | Jun 14, 2019

Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

...Novartis Oncology after only 11 months on the job, to become president and CEO of Urogen...
...Munich, Germany Spark Therapeutics Inc. (NASDAQ:ONCE), Philadelphia, Pa. Takeda Pharmaceutical Co. Ltd. (JASDAQ:4502), Tokyo, Japan UroGen...

BioCentury | Jan 25, 2019

Financial News

UroGen, Wave each raise $150M follow-ons

...NASDAQ:URGN) and Wave Life Sciences Ltd. (NASDAQ:WVE) each raised $150 million in follow-ons. Uro-oncology company UroGen...
...Steps in as CEO, UroGen Reports 57% Complete Response Rate for Urothelial Cancer Therapy" ). UroGen...
...UroGen Pharma Ltd. (NASDAQ:URGN), Ra'anana, Israel Wave Life Sciences Ltd. (NASDAQ:WVE), Cambridge, Mass. Chris Lieu suvodirsen (WVE-210201) UGN-101 (mitogel) UroGen...

BioCentury | Jan 24, 2019

Financial News

UroGen, Wave each raise $150M follow-ons

...NASDAQ:URGN) and Wave Life Sciences Ltd. (NASDAQ:WVE) each raised $150 million in follow-ons. Uro-oncology company UroGen...
...the company's close of $53.66 on Tuesday, when it proposed the offering after market hours. UroGen...
...Steps in as CEO, UroGen Reports 57% Complete Response Rate for Urothelial Cancer Therapy" ). UroGen...

BioCentury | Jan 23, 2019

Company News

Management tracks: Cabaletta, Sage, MyoKardia

...appointed Elizabeth Barrett and George Golumbeski to its board. Barrett became president and CEO of UroGen...

Items per page:

1 - 10 of 73

BioCentury | Dec 21, 2020

Management Tracks

CFO transitions at Translate, Spero, Ziopharm, Precision, CASI, Tessa, Kiniksa and Aquestive; plus updates from 3T, Novavax, Alnylam and more

...Myers as CMO. Greenleaf is CEO of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH; TSX:AUP). Bryan joins from UroGen...

BioCentury | Dec 3, 2020

Management Tracks

Management Tracks: Zai taps Sandler as cancer head, plus moves at FibroGen, Arena, Samumed, Avita, Mersana, Frequency, Matinas, NeuBase, Allena and RA

...at Bristol Myers Squibb Co. (NYSE:BMY).Peter Pfreundschuh joined degenerative disease company Frequency Therapeutics Inc. (NASDAQ:FREQ) as CFO. He was CFO at UroGen...

BioCentury | Apr 16, 2020

Product Development

April 15 Quick Takes: TScan, Novartis team up on TCR therapies and a first for UroGen; plus Aligos, Leo, Madrigal, Merck

BioCentury | Mar 28, 2020

Management Tracks

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

BioCentury | Jul 13, 2019

Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...NASDAQ:WVE) 1/24/19 $150.1 $1,268.3 $893.8 -30% Bellerophon Therapeutics Inc. (NASDAQ:BLPH) 1/23/19 $7.0 $48.1 $41.3 -14% UroGen...

BioCentury | Jun 29, 2019

Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...Pharmaceutical Inc. (NASDAQ:RARE) Triheptanoin (UX007) Treat long-chain fatty acid oxidation disorders (LC-FAOD) Submit NDA Mid-2019 UroGen...

BioCentury | Jun 14, 2019

Product Development

1 - 10 of 73

CFO transitions at Translate, Spero, Ziopharm, Precision, CASI, Tessa, Kiniksa and Aquestive; plus updates from 3T, Novavax, Alnylam and more

Management Tracks: Zai taps Sandler as cancer head, plus moves at FibroGen, Arena, Samumed, Avita, Mersana, Frequency, Matinas, NeuBase, Allena and RA

April 15 Quick Takes: TScan, Novartis team up on TCR therapies and a first for UroGen; plus Aligos, Leo, Madrigal, Merck

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

How crossover, insider support and big money correlated with performance across 1H19 IPOs

All eyes on new modality launches, cancer and rare disease data in 3Q19

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

UroGen, Wave each raise $150M follow-ons

UroGen, Wave each raise $150M follow-ons

Management tracks: Cabaletta, Sage, MyoKardia

CFO transitions at Translate, Spero, Ziopharm, Precision, CASI, Tessa, Kiniksa and Aquestive; plus updates from 3T, Novavax, Alnylam and more

Management Tracks: Zai taps Sandler as cancer head, plus moves at FibroGen, Arena, Samumed, Avita, Mersana, Frequency, Matinas, NeuBase, Allena and RA

April 15 Quick Takes: TScan, Novartis team up on TCR therapies and a first for UroGen; plus Aligos, Leo, Madrigal, Merck

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

How crossover, insider support and big money correlated with performance across 1H19 IPOs

All eyes on new modality launches, cancer and rare disease data in 3Q19

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

UroGen, Wave each raise $150M follow-ons

UroGen, Wave each raise $150M follow-ons

Management tracks: Cabaletta, Sage, MyoKardia

Products & Solutions

About Biocentury

Contact

Privacy & Legal